Intelligence Profile
Safety Profile
The safety profile of cagrilintide is primarily derived from studies examining CagriSema, a combination therapy containing both cagrilintide and semaglutide. Evidence on the safety of cagrilintide as a monotherapy is limited, as most clinical data comes from combination studies.
Known Side Effects
Based on the available evidence from phase 3 trials (REIMAGINE 1 and REIMAGINE 2 studies), safety data exists for the cagrilintide-semaglutide combination in adults with type 2 diabetes. However, specific side effect profiles attributable solely to cagrilintide are not clearly delineated in the available evidence. The studies primarily report safety outcomes for the combination therapy rather than individual components.
Contraindications and Precautions
No specific contraindications for cagrilintide monotherapy are detailed in the available evidence. The safety data comes predominantly from combination therapy studies, making it difficult to isolate contraindications specific to cagrilintide alone.
Drug Interactions
Evidence regarding drug interactions with cagrilintide is not provided in the available research. The clinical studies focus primarily on efficacy outcomes and general safety profiles rather than specific drug-drug interactions.
Special Populations
The available evidence includes limited information about use in special populations:
- Pediatric use: One phase 3 trial (NCT07282613) is planned to study CagriSema in children and adolescents with type 2 diabetes, but results are not yet available
- Pregnancy and lactation: No safety data is provided in the available evidence
- Elderly populations: Specific safety considerations for elderly patients are not detailed in the available studies
- Renal or hepatic impairment: No information about use in patients with organ impairment is provided
Evidence Limitations
The safety profile of cagrilintide is significantly limited by several factors:
- Most data comes from combination therapy studies (cagrilintide with semaglutide), making it difficult to attribute safety signals to cagrilintide specifically
- Monotherapy safety data is sparse in the available evidence
- Long-term safety data beyond clinical trial durations is not available
- Safety in special populations is largely unstudied or unreported
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Patients should consult with their healthcare providers before starting, stopping, or changing any medication regimen. Individual safety profiles may vary based on patient-specific factors not covered in clinical trial populations.
Healthcare providers should refer to the most current prescribing information and regulatory guidance for complete safety information, as the available research evidence provides limited detail on the comprehensive safety profile of cagrilintide.